- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07483450
En studie för att utvärdera effekt, säkerhet, farmakokinetik och farmakodynamik hos ocrelizumab hos deltagare med återkommande multipel skleros och primär progressiv multipel skleros
En multicenter, öppen, enarmsstudie för att utvärdera effekt, säkerhet, farmakokinetik och farmakodynamik hos ocrelizumab hos kinesiska patienter med återkommande multipel skleros och primär progressiv multipel skleros
The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
-
Beijing, Kina, 100034
- Peking University First Hospital
-
Beijing, Kina, 100032
- Peking Union Medical College Hospital
-
Beijing, Kina, 100730
- Beijing Hospital of Ministry of Health
-
Changsha, Kina, 410008
- Xiangya Hospital Central South University
-
Chengdu, Kina, 610041
- West China Hospital of Sichuan University
-
Chongqing, Kina, 400016
- The First Affiliated Hospital, Chongqing Medical University
-
Guangzhou, Kina, 510080
- The First Affiliated Hospital of Sun Yat-sen University
-
Guangzhou, Kina, 510630
- The Third Affiliated Hospital of Sun Yat-Sen University
-
Hangzhou, Kina, 310003
- The First Affiliated Hospital of College of Medicine, Zhejiang University
-
Hohhot, Kina, 010011
- Inner Mongolia Autonomous Region People's Hospital
-
Lanzhou, Kina, 730030
- Lanzhou University Second Hospital
-
Shenyang, Kina, DUMMY_VALUE
- The First Hospital of China Medical University
-
Shijiazhuang, Kina, 050000
- The Second Hospital of Hebei Medical University
-
Taiyuan, Kina, 030000
- 1st Affiliated Hospital of Shanxi Medical University
-
Wuhan, Kina, 430030
- Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
-
Ürümqi, Kina, 830000
- Xinjiang People Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330209
- The First Affiliated Hospital of Nanchang University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Diagnosis of RMS/PPMS in accordance with the revised 2017 McDonald Criteria
- EDSS score from 0-5.5 (RMS) or 3.0-6.5 (PPMS), inclusive, at screening and baseline
- Documented MRI of brain with abnormalities consistent with MS before screening
Exclusion Criteria:
- Diagnosis of PPMS or non-active secondary progressive multiple sclerosis (SPMS) (only for RMS cohort)
- History of relapsing remitting multiple sclerosis (RRMS) or SPMS at screening (only for PPMS cohort)
- Disease duration of more than 10 years in participants with an EDSS ≤ 2.0 at screening (only for RMS cohort)
- History of confirmed or suspected progressive multifocal leukoencephalopathy (PML)
- Inability to complete an MRI scan or contraindication to Gd administration
- Contraindications to mandatory pre-medications (i.e., corticosteroids and antihistamines)
- Known presence of other neurologic disorders if they could interfere with the diagnosis of MS or assessments of efficacy and/or safety during the study
- Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
- Known history of human immunodeficiency virus (HIV) infection
- Lack of peripheral venous access
- Previous treatment with B-cell targeted therapies (i.e., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab), unless the last infusion was at least 6 months prior to screening
- Positive screening tests for hepatitis B virus (HBV) and/or hepatitis C virus (HCV)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: RMS Cohort
Participants with RMS will receive ocrelizumab, 300 milligrams (mg), intravenous (IV) infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, for all subsequent cycles every 24 weeks (Q24W) (1 Cycle=24 weeks). |
Ocrelizumab will be administered as per the schedule specified in the respective arms.
Andra namn:
|
|
Experimentell: PPMS Cohort
Participants with PPMS will receive ocrelizumab, 300 mg, IV infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, at Week 24 (1 Cycle=24 weeks). |
Ocrelizumab will be administered as per the schedule specified in the respective arms.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
RMS-kohort: Årlig protokoll-definierad återfallsgrad
Tidsram: Upp till cirka 1,6 år
|
Upp till cirka 1,6 år
|
|
PPMS-kohort: B-cellnivåer i blod
Tidsram: Upp till vecka 48
|
Upp till vecka 48
|
|
PPMS-kohort: Andel deltagare som uppnår Cluster of Differentiation 19 (CD19+) B-cellsnivåer på <10 celler/mikroliter (μL) vid vecka 48
Tidsram: Vid vecka 48
|
Vid vecka 48
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
RMS-kohort: Procentandel deltagare som inte har några tecken på sjukdomsaktivitet (NEDA3) under en 48-veckorsperiod
Tidsram: Upp till vecka 48
|
Upp till vecka 48
|
|
|
RMS-kohort: Procentandel deltagare utan återfall vid vecka 48
Tidsram: Upp till vecka 48
|
Upp till vecka 48
|
|
|
RMS-kohort: Andel deltagare med NEDA3 under en 24-veckorsperiod
Tidsram: Upp till vecka 24
|
Upp till vecka 24
|
|
|
RMS-kohort: Totalt antal T1-gadolinium (Gd)-förstärkande läsioner enligt detektering med magnetisk resonanstomografi (MRI) av hjärnan
Tidsram: Upp till vecka 48
|
Upp till vecka 48
|
|
|
RMS-kohort: Totalt antal nya eller förstorade T2-hyperintensa lesioner som detekterats av hjärn-MRI
Tidsram: Upp till vecka 48
|
Upp till vecka 48
|
|
|
RMS- och PPMS-kohorter: Förändring från baseline till vecka 48 i koncentrationen av serum neurofilament light chain (NfL)
Tidsram: Baslinje upp till vecka 48
|
Baslinje upp till vecka 48
|
|
|
RMS- och PPMS-kohorter: Serumkoncentration av Ocrelizumab
Tidsram: Upp till vecka 48
|
Upp till vecka 48
|
|
|
RMS Kohort: B-cellnivåer i Blodet
Tidsram: Upp till vecka 48
|
Upp till vecka 48
|
|
|
RMS-kohort: Procentandel deltagare som uppnår CD19+ B-cellsnivåer på <10 celler/µL vid vecka 48
Tidsram: Vid vecka 48
|
Vid vecka 48
|
|
|
PPMS-kohort: Totalt antal T1 Gd-förstärkande lesioner som upptäckts med hjärn-MRI vid vecka 24 och vecka 48
Tidsram: Vecka 24 och Vecka 48
|
Vecka 24 och Vecka 48
|
|
|
PPMS-kohort: Totalt antal nya eller förstorade T2-hyperintensa lesioner som detekterats med hjärn-MRI vid vecka 24 och vecka 48
Tidsram: Vecka 24 och vecka 48
|
Vecka 24 och vecka 48
|
|
|
RMS- och PPMS-kohorter: Antal deltagare med biverkningar (AE)
Tidsram: Upp till cirka 1,8 år
|
Upp till cirka 1,8 år
|
|
|
RMS- och PPMS-kohorter: Förändring från baslinje i T-cellnivå
Tidsram: Upp till ungefär 1,8 år
|
Upp till ungefär 1,8 år
|
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Expanded Disability Status Scale (EDSS)
Tidsram: Baseline up to Week 48
|
EDSS is a scale for assessing neurologic impairment in participants with multiple sclerosis (MS). EDSS is based on a standard neurological examination, incorporating functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral [or mental]) that are rated and then scored as a functional systems scores (FSS), and ambulation, which is scored as ambulation score. Each FSS is an ordinal clinical rating scale ranging from 0 to 5 or 6 and an ambulation score that is rated from 0 to 16. These ratings are then used in conjunction with observations, as well as information, concerning ambulation and use of assistive devices to determine the total EDSS score. Values are from 0 points (normal neurological examination) up to 10 points (death), increasing in increments of 0.5 points. Higher scores represent increased disability. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Timed 25-Foot Walk Test (T25FWT)
Tidsram: Baseline up to Week 48
|
The T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant is directed to start at one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly and safely as possible and immediately walk back the same distance. Score for the T25FWT is the average of the two completed trials. The time taken to complete the test is measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. A 20% change from baseline of the averaged T25FWT is typically considered clinically meaningful. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline to Week 48 in 9-Hole Peg Test (9-HPT)
Tidsram: Baseline up to Week 48
|
The 9-HPT is a performance measure used to assess upper extremity (arm and hand) function. Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time indicates higher raw scores, which indicates deterioration. A 20% change from baseline is typically considered clinically meaningful. |
Baseline up to Week 48
|
|
RMS and PPMS Cohorts: Change From Baseline in EuroQoL 5-Dimension Questionnaire (5-Level Version; EQ-5D-5L) Index Score at Week 48
Tidsram: Baseline, Week 48
|
The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. |
Baseline, Week 48
|
|
RMS and PPMS Cohorts: Percentage of Participants With Suicidal Ideation or Behaviour, as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Tidsram: Up to approximately 1.8 years
|
C-SSRS is an assessment tool used to assess lifetime suicidality of participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, and attempts with actual/potential lethality. Categories have binary responses (yes/no) and include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher indicate suicidal ideation or behavior. |
Up to approximately 1.8 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Clinical Trials, Hoffmann-La Roche
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Sjukdomar i nervsystemet
- Patologiska processer
- Kronisk sjukdom
- Sjukdomsegenskaper
- Autoimmuna sjukdomar
- Immunsystemets sjukdomar
- Demyeliniserande autoimmuna sjukdomar, CNS
- Autoimmuna sjukdomar i nervsystemet
- Demyeliniserande sjukdomar
- Patologiska tillstånd, tecken och symtom
- Multipel skleros
- Multipel skleros, kronisk progressiv
- ocrelizumab
Andra studie-ID-nummer
- YN44938
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .